BioGene Therapeutics Adds Veteran Biopharma Executive Ty Howton to Board
SLDB•BioGene Therapeutics has added Ty Howton, ex-COO of Solid Biosciences and former General Counsel at Vertex and Sarepta, to its Board. Howton’s 30-year biopharma tenure includes overseeing multiple equity financings, debt facilities and advancing gene therapy candidates into active clinical trials.
1. Board Appointment
BioGene Therapeutics appointed Ty Howton to its Board, effective immediately. His addition aims to strengthen governance and strategic oversight as the company pursues growth in gene therapy and related vascular therapeutics.
2. Executive Track Record
Howton brings nearly 30 years of industry experience, having served as Chief Operating Officer at Solid Biosciences and held senior legal and compliance roles at Vertex Pharmaceuticals, Sarepta Therapeutics and Genentech. He contributed to product launches such as Incivek and Kalydeco and guided multiple companies through clinical-to-commercial transitions.
3. Financing and Growth Expertise
Throughout his career, Howton has facilitated multiple series-stage equity financings, non-dilutive funding arrangements and debt facilities, driving market capitalization growth. His track record in structuring capital raises is expected to support BioGene Therapeutics’ future financing initiatives and pipeline advancement.
